Stella Martomo
Senior Director, Translational Sciences EvolveImmune Therapeutics, Inc.
Seminars
Wednesday 24th June 2026
Advancing the EVOLVE Platform with Integrated CD2 Costimulation to Enhance the Depth of T-Cell Engager Responses & Prevent Early Therapeutic Exhaustion
2:30 pm
- T‑cell engagers have shown positive clinical outcomes across multiple indications, including solid tumors, but currently approved molecules do not provide a direct co‑stimulatory signal
- The EVOLVE platform integrates CD2 co‑stimulation into CD3 multispecifics to enhance T‑cell activation, durability, and functional fitness
- An overview of the EVOLVE multispecific platform and highlight key design features that enable improved T‑cell engagement
